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Background: Neural tube defects (NTDs) are some of the most common congenital anomalies. Proper folic
acid supplementation is a dominant risk factor, which has been shown to decrease the incidence of NTDs. In
Canada, the incidence of neuroblastoma has presented a considerable decrease of 60% as a result of enrichment
cereal grain flours with synthetic folic acid. The aim of this study was to investigate the effect of folic acid intake
by pregnant women on the incidence of NTDs and neuroblastoma.
Methods: Regular folic acid intake has been recommended to pregnant women in Hungary since the eighties
of the last century by health visitors eventually raking effect as an official protocol which had been released in
1997. During 2001, 2002 and 2003, folic acid intake habits of pregnant women were evaluated by health visitors,
proving to be successful in collecting data from 95.06% of the pregnant women. The incidence of NTDs has been
registered by the Hungarian National Centre of Epidemiology, Department of Human Genetics and Teratology.
The Pediatric Cancer Registry provided the incidence of neuroblastoma in children.
Results: Consistent findings revealed a regular intake of supplementary folic acid products by 68.71% of the
pregnant women. Out of these, 93.13% of pregnant women who were taking folic acid, started the supplemen-
tation after their 7 weeks of pregnancies, a time designated as the completion period of the development of the
neural tube. The dose of folic acid supplementation was evaluated as less than 5 mg/day in 84.75% of the
pregnant women. In Hungary, the incidence of NTDs has remained constant, while the incidence of neuroblas-
toma has shown constant slight increase in spite of the introduction of folic acid supplementation in 1997.
Conclusions: Based on our experience, folic acid supplementation was initiated after the recognition of
pregnancy and its application in a dose of lower than 5 mg/day neither decreased the incidence of NTDs nor did
it have an effect on the neuroblastoma incidence. It is implicated that proper folic acid supplementation, which
is started from the conception, can be achieved only with the enrichment of cereal grain flours.
INTRODUCTION
The effect of folic acid on the development of congenital
anomalies was first described by Smithills and Hibbard in 1965
[1]. Since then, several studies have confirmed that depending
on the dose, folic acid administration started before the preg-
nancy moderates the occurrence of neural tube anomalies
[2–7]. In Hungary, Czeizel et al. proved in a double-blind
randomised study that folic acid supplementation in a dose of
0.8 mg/day started before the pregnancy can prevent the de-
velopment of neural tube defects (NTDs) [8]. Neuroblastoma is
a malignant disorder of the primitive sympathetic neural sys-
tem. In 2003, a Canadian study described that since the intro-
duction of folic acid fortificated flour, the occurrence of neu-
roblastoma has shown a considerable decrease by 60% [9].
The benefits of medicine and/or medical nutriment use
Address reprint requests to: Miklo´s Garami, M.D., M.Sc., Ph.D., Head, Unit of Pediatric Oncology, 2nd Department of Pediatrics, Faculty of Medicine, Semmelweis
University, Tu¨zolto´ u. 7–9, Budapest, H-1094, HUNGARY. E-mail: miklos.garami@gyer2.sote.hu
The authors have declared no conflict of interest.
This work has been supported by the Hungarian Scientific Research Fund (OTKA) Contract No. T-04639 and by the National Research and Development Fund (NKFP)
Contract No. 1A/002/2004.
Contributers: M. Bogna´r and M. Garami coordinated the study and were involved in the study design, analysis, and interpretation of results and writing of the report.
A. Ponyi and P. Hauser interpreted the results. Zs. Jakab and J. Mu¨ller contributed to the data collection and performed the statistical analysis. T. Constantin helped the
design and initiated the study. D Schuler formed the hypothesis and guided the study.
Journal of the American College of Nutrition, Vol. 27, No. 4, 499–504 (2008)
Published by the American College of Nutrition
499
during pregnancy are not restricted to the recovery of maternal
health but also result in some advantages for the fetus as well,
because the maternal well-being is important for the optimal
development of the fetus. The low number of the planed preg-
nancies in Hungary is one of the major causes of the improper
use of folic acid.
Our aim was to study whether folic acid supplementation
that started after the recognition of pregnancy and given in a
dose of 0.8 mg daily according to the official recommendation
in Hungary, can decrease the frequency of NTDs and whether
any relations between the administration of folic acid during
the pregnancy and the occurrence of neuroblastoma can be
found.
METHODS
Participants and Study Design
A retrospective, cross-sectional, nationwide study was de-
signed to investigate the folic acid administration habits of
Hungarian pregnant women. The frequency of NTDs and neu-
roblastomas were also studied. During 2001, 2002 and 2003,
analyses were conducted resulting in the collection of a con-
siderable amount of data in these three years. The folic acid
intake habits were observed and recorded in written forms
during the pregnancies. The survey was conducted, based on a
questionnaire-based personal data collection by health visitors,
which was governed by the delivery of 4,630 forms to the
country’s 20 welfare centres. The questionnaire form was con-
structed to obtain a clear picture of folic acid intake routine
among pregnant women. The answers to the following ques-
tions were sought through this questionnaire: (i) During your
pregnancy, have you taken any folic acid medication? If so,
regularly or sometimes only?; (ii) From which week of the
pregnancy did you begin to take the folic acid?; (iii) Which
product did you take?; and (iv) Please quote the number of
tablets per day? Moreover, we separately specified the time
when women did not take any folic acid products, or there were
no available data about the given pregnant woman. Gathering
information about the factory product and the daily quantity,
the daily dose was calculated.
Between 2001 and 2003, 285,884 children were born in
Hungary, according to the data of the Hungarian National
Statistical Office. The completed questionnaires covered the
data of 271,748 pregnant women, which accounted for 95.06%
of the pregnant women from 2001 till 2003.
All pediatric cancer patients in Hungary are now registered
and followed in the Hungarian Pediatric Cancer Registry. Our
registry contains patient identification information, date of di-
agnosis, histological findings (and in solid tumors, stage and
primary site of the tumor), treatment and outcome of the
oncology treatment (relapses, survival rates) [10].
Written informed consent was obtained for participation in
all cases. The study conformed to ethical standards currently
applied in Hungary. Data are collected regularly from the
pregnant women by health visitors regarding the condition of
the conceptions and the pregnancies. These data collection
procedure have the Medical Scientific Board approval. Our
data cover a part of the above mentioned data collection pro-
cedure. This study does not require any additional ethical
approval.
Statistical Analysis
The obtained data were entered into SPSS for Windows
10.0 statistics software (SPSS Inc., Chicago, IL, USA). Almost,
one and a half million data were processed into computer for
statistical analysis. Breakdown analysis and regression calcu-
lation were performed.
RESULTS
As Fig. 1 illustrates, 186,713 (68.71%) of the pregnant
women took folic acid containing products regularly, 22,179
(8.16%) had a frequent intake and 41,993 (15.45%) never took
them at all. However, the data concerning 20,863 (7.68%) of
the pregnant women were missing. The regular intake of folic
acid varied in different countries of Hungary ranging between
61–80%; however, there was no relation between the fre-
quency of the regular intake and the geographical location of
the countries.
During the analyzed years, 95,783 (45.85%) of the pregnant
women started taking folic acid in the first, 87,075 (41.68%) in
the second and 26,034 (12.46%) in the third trimester, respec-
tively. Week-based breakdown of starting the folic acid intake
Fig. 1. Fashion of folic acid intake of Hungarian pregnant women
during three years (2001–2003). Based on the data, it can be stated that
186,713 (68.71%) of pregnant women were consuming drugs contain-
ing folic acid regularly, 22,179 (8.16%) less frequently and 41,993 of
them did not consume it (15.45%) at all. There were no available data
about 20,863 (7.68%) of pregnant women.
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is shown on Fig. 2. Majority of the pregnant women started the
supplementation in weeks 7–12. Thus, a high percentage of the
pregnant women started the intake of the various folic acid
containing drugs after the closure of the neural tube. Between
weeks 0 and 6, 14,353 (6.87%) of the pregnant women started
the intake of folic acid. We suppose that these were planned
pregnancies. A significant majority of the regular consumers
(84.75%) took a daily dose of less than 5 mg [11–13].
Based on the data of the National Centre for Epidemiology,
Department of Human Genetics and Teratology, since 1997,
the number of NTDs has been almost constant in Hungary: in
the year 1997, it was estimated as 0.5/1000 whereas in 2002, it
was 0.6/1000 children. As presented in Fig 3, the incidence of
neuroblastoma has varied since 1975 in Hungary, but it shows
a slightly increasing trend according to the National Pediatric
Cancer Registry. During 2001–2003, 45% of children with
neuroblastoma were less than 1 year old, another 45% were
between 1–5 years of age, 6% were between 5–10 years and 4%
were between 10–14 years. It was evident that 90% of the
patients with neuroblastoma were younger than 5 years, which
was a rate being higher as compared with international data
(66%) [14].
DISCUSSION
Several international and Hungarian studies proved that the
incidence of neural tube anomalies can be decreased by folic
acid administration during pregnancy. Five of six studies pub-
lished about a decrease of about 40 to 100% in the frequency of
NTDs in cases where folic acid was consumed on a daily basis
[3,4,8,15–17]. In these studies, the daily dose of folic acid alone
or part of a multivitamin substance, varied between 0.4 mg and
5 mg, and its intake was started at least one month before
conception and continued during the first trimester. According
to some publications, folic acid moderates the occurrence of
NTDs depending on the dose: increasing the daily dose with 0.4
mg means a decrease of 36%, while at 5 mg, the decrease is
85% [11–13,18,19]. However, as regards the optimal dose,
there is yet no international agreement.
Hungarian and foreign recommendations differ in terms of
the daily folic acid quantity. United States Public Health Ser-
vice recommends that “all women of childbearing age in the
United States who are capable of becoming pregnant should
consume 0.4 mg of folic acid per day for the purpose of
reducing their risk of having a pregnancy affected with spina
Fig. 2. Week-based breakdown of starting folic acid intake. The majority of pregnant women started the supplementation in weeks 7–12. Thus, a high
percentage of pregnant women started the intake of the various folic acid containing drugs after the closure of the neural tube. Between weeks 0 and
6, only 6.87% of pregnant women started the intake of folic acid.
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bifida or other NTDs” (Centres for Disease Control and Pre-
vention, 1992) [7]. In 1998, the US National Academy of
Sciences’ Institute of Medicine recommended that all women
of childbearing age should consume 0.4 mg of synthetic folic
acid per day from fortified foods and/or supplements in addi-
tion to folate from a varied diet. The Institute of Medicine
specified the preference for synthetic folic acid because of its
greater bioavailability than food folate. In England, based on
the British Medical Research Council Medical Study recom-
mendation, the suggested quantity is 4 mg for the women who
already had a child with neural tube anomaly [6]. Wald et al.
recommended that the daily folic acid dose should be raised to
5 mg/day for every fertile woman [11]. Kierke et al. stressed
that the daily folic acid intake should not exceed 1 mg unless
the substance is prescribed by a professional doctor in certain
cases, because it may cover-up the symptoms of B12- defi-
ciency [20]. However, there are other publications which did
not confirm this observation [21].
In Hungary, health visitors have recommended folic acid
intake to pregnant women since the eighties of the last century.
The official recommendation of the Obstetric and Gynaecologi-
cal Professional Board was published in 1997, which states that
all fertile women should daily take 0.4 mg folic acid while
those who are at risk with NTDs should take 0.8 mg daily. The
starting day of folic acid consumption has a paramount impor-
tance: the fetal nervous system develops most dynamically
during the first trimester, and the neural tube closes between the
days 24–30 (in average on the 28th day) which is often before
the recognition of the pregnancy. There are no available data
whether the supplementation of folic acid started later has any
effect on the already established developmental anomalies. The
optimal prevention consists of administration of folic acid in an
optimal daily dose for every fertile woman. Enrichment of flour
with folic acid for the prevention of neural tube anomalies
started in 1997 in Canada and in 1998 in the USA [22,23].
Addition of 0.14 and 0.15 mg folic acid to 100 gram flour
resulted in a 31% and 16% decrease of the incidence of spina
bifida and anencephaly, respectively [24–26].
In the current study, we performed a nation-wide survey
collecting data about folic acid intake habits of pregnant
women through questionnaires circulated during 2001, 2002
and 2003 in Hungary. Data of 271,748 young mothers were
collected and more than 1 million data were obtained. Accord-
ing to our results, 68.1% of the pregnant women presented a
regular consumption of some folic acid containing substance.
Despite the regular folic acid intake, the frequency of NTDs did
not show a decreasing tendency. However, it could be a bias
that only 68.1% of the pregnant women took folic acid. It was
not possible to identify the number of children born from
mothers’ on a regular consumption-, frequent consumption and
no consumption of any folic acid supplementation. Hence, we
compared the number of children born from all the three groups
with historical control. It may be a further bias that the registry
of developmental anomalies is not of proper accuracy in Hun-
gary. The suggested average reporting ratio of the past years
was 40%. Czeizel E. et al made a nationwide data collection to
analyze the NTDs frequencies in Hungary between 1963–1967
[27]. They concluded that the frequency of NTDs was 2.95/
1000 newborn babies in Hungary. This investigation had been
reconfirmed in 1992, 1994 and 2004 by these authors [8,28,29].
These studies underline the fact, that the reported NTDs from
Hungarian National Centre of Epidemiology, Department of
Human Genetics and Teratology are representing an insuffi-
cient number of NTDs. This is supported by the fact that in
other countries, the frequency of these developmental anoma-
lies is much higher. The number of reported cases in Hungary
is 0.5–0.6/1000, while it is 2.4–3.7/1000 in England and Ire-
land, 1.6–2.0/1000 in Australia, and 1–2/1000 in the USA
Fig. 3. Incidence of neuroblastoma in Hungary between 1975 and 2003; age: 0–4 years. According to The National Paediatric Cancer Registry, the
incidence of neuroblastoma has varied in Hungary since 1975, but has shown a slightly increasing trend.
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[30,31]. However, the incomplete reporting of the developmen-
tal anomalies itself does not explain the fact that after intro-
ducing the folic acid prophylaxis, the number of NTDs did not
decrease. Based on our experience, the prophylactic supple-
mentation of folic acid begins in Hungary later than the date of
neural tube closure in more than 90% of the pregnant women.
A further observation was that the daily dose of folic acid was
less than that recommended by Wald et al. in 85% of the
pregnant women [11]. Thus, we can conclude that the currently
applied folic acid supplementation method is not a proper
prophylaxis in Hungary despite the hard work of health visitors
and good compliance of the pregnant women. The increasing
number of planned pregnancies would enable to start the intake
of substances containing folic acid earlier by pregnant women.
General practitioners and gynaecologists should provide avail-
able information and should recommend folic acid intake to
women in their fertility period. Social campaigns, posters and
brochures could help in drawing attention to the benevolent
effect of folic acid. However, this study also proves that the
whole targeted population can be reached only if the folic acid
is mixed with everyday food, e.g. flour.
A further surprising observation according to a Canadian
survey performed in 2003, is that the mixing of folic acid into
the flour decreased the incidence of neuroblastoma by 60% [9].
Based on the data provided by The National Pediatric Cancer
Registry, the incidence of neuroblastoma has varied since 1975,
showing a slightly increasing tendency in Hungary. The inci-
dence did not reveal any significant change in 68.7% of preg-
nant women, after the folic acid prophylaxis was started. Our
study showed that increased maternal folic acid intake during
the pregnancy does not decrease the risk of neuroblastoma.
However, the folic acid intake began during the first trimester
of pregnancy in 45.85%, during the second trimester in 41.68%
and during the third trimester in 12.46%, respectively. It is
possible that the decreased incidence of neuroblastoma ob-
served in Canada after the introduction of the enrichment of
flour by folic acid was due to an increased folic acid intake
initiated already before the conception and continued even after
delivery or it was due to other environmental factors besides
the increased folic acid intake.
In each year approximately 5,000 pregnancies are affected
by NTDs in the European Union (EU). Most of the EU coun-
tries have a public health strategy similar to the one followed in
Hungary, regarding the primary prevention of NTDs [32].
However, the Canadian experience and our current study
proved that public education campaigns would not be effective
alone in achieving optimal preconceptional folic acid intake for
the majority of women [33]. The “Canadian like” public health
strategy, based on food fortification with folic acid, defined that
all women in their childbearing age who increased their dietary
intake of folic acid effectively, consequently decreased the
frequency of NTDs [18,19,32–34]. Based on a more than five
year long experience, it is worth considering changing not only
the Hungarian, but the EU public health strategy about folic
acid intake by pregnant woman to prevent and/or reduce the
number of NTDs.
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